BFRI Biofrontera Inc. - Fundamental Analysis
BEARISH
Sign in to save
Save this symbol to a watchlist or track a position.
BFRI Stock | Fundamental Analysis & Investment Insights
NASDAQ
Healthcare
Drug Manufacturers - Specialty & Generic
Current Price
Live
$1.0
Analyst Target
$6.0
+500.0%
Upside
52W High
$1.24
52W Low
$0.54
At a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
85%
Analysis Accuracy
The Advanced Deterministic Scorecard reveals a critically weak financial profile with a Piotroski F-Score of just 1/9, indicating severe operational and financial distress. Despite a gross margin of 64.41%, the company is deeply unprofitable with negative operating leverage, deteriorating revenue, and an ROE of -1191.73%. The stock trades at a significant discount to the analyst target price of $6.00, but this appears unjustified given the persistent earnings misses, negative valuation multiples, and lack of financial stability. Recent short-term price strength is likely speculative, as fundamentals continue to deteriorate.
Key Strengths
High gross margin (64.41%) suggests pricing power or low production costs in core operations
Analyst consensus recommendation is strong_buy, indicating potential upside recognition
Price/Sales ratio of 0.31 is low, potentially signaling undervaluation relative to sales
Current ratio of 1.15 indicates minimal short-term liquidity coverage
Recent 1-month price return of +38.9% shows possible market sentiment shift or speculative interest
Key Risks
Piotroski F-Score of 1/9 signals extreme financial weakness and high risk of continued underperformance
Negative Price/Book (-4.50) and Forward P/E (-4.35) imply negative book value and sustained losses
Revenue growth YoY of -22.50% reflects shrinking top line and declining market demand or execution failure
ROE of -1191.73% indicates catastrophic return on equity, driven by accumulated losses and equity erosion
Lack of Altman Z-Score due to incomplete data, but negative equity and high leverage likely place it in distress zone (<1.8)
AI Fair Value Estimate
Based on comprehensive analysis
$1.0
0.0% below current price
Performance Snowflake
Multi-dimensional AI analysis across 5 key categories
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Historical Performance Trends
Long-term financial metrics and growth patterns
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability, Growth & Financial Health
Detailed profit margins, ROE, debt ratios, and liquidity metrics
Sector Comparison & Peer Analysis
Compare BFRI against industry averages and similar companies
Insider Trading & Analyst Ratings
Track insider transactions and Wall Street analyst recommendations
Past News Coverage
Recent headlines mentioning BFRI from our newsroom.
Newest → oldest
No matching news yet.